Inventor · disambiguated record
Alexander D. Mackerell, Jr.
Also filed as: MACKERELL ALEXANDER · MACKERELL ALEXANDER D · MACKERELL ALEXANDER D JR · MACKERELL JR ALEXANDER
28 granted patents·22 pending applications·100 citations·filing 2001–2025
95Inventor score
Top patents by PatentIndex Score
50 records- 0196US11357781B2Non-catalytic substrate-selective, p38α-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereofUNIV MARYLAND·Filed 2021·Granted Jun 14, 2022·10 cites·21 claims
- 0296US11078171B2Non-ATP/catalytic site p38 mitogen activated protein kinase inhibitorsUNIV MARYLAND·Filed 2020·Granted Aug 3, 2021·13 cites·13 claims
- 0394US11718595B2Non-ATP/catalytic site p38 Mitogen Activated Protein Kinase inhibitorsUNIV MARYLAND·Filed 2021·Granted Aug 8, 2023·4 cites·19 claims
- 0493US11911393B2Non-catalytic substrate-selective p38alpha-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereofUNIV MARYLAND·Filed 2023·Granted Feb 27, 2024·1 cites·17 claims
- 0591US11911392B2Non-catalytic substrate-selective p38α-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereofUNIV MARYLAND·Filed 2022·Granted Feb 27, 2024·1 cites·20 claims
- 0690US9115122B2Non-ATP dependent inhibitors of extracellular signal-regulated kinase (ERK)SHAPIRO PAUL S·Filed 2013·Granted Aug 25, 2015·9 cites·4 claims
- 0790US8338464B2Small molecule inhibitors of BCL6MELNICK ARI MATTHEW·Filed 2007·Granted Dec 25, 2012·35 cites·12 claims
- 0885US7915245B2Methods and compositions of trail-death receptor agonists/activatorsUNIV TEXAS·Filed 2007·Granted Mar 29, 2011·10 cites·8 claims
- 0984US2025100985A1NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORSUNIV MARYLAND·Filed 2024·Application pending·0 cites
- 1082US12404259B2Inhibitors of extracellular signal-regulated kinaseGEN1E LIFESCIENCES INC·Filed 2024·Granted Sep 2, 2025·0 cites·12 claims
- 1182US2024366619A1NON-CATALYTIC SUBSTRATE-SELECTIVE p38alpha-SPECIFIC MAPK INHIBITORS WITH ENDOTHELIAL-STABILIZING AND ANTI-INFLAMMATORY ACTIVITY, AND METHODS OF USE THEREOFUNIV MARYLAND·Filed 2024·Application pending·0 cites
- 1281US12202810B2Non-ATP/catalytic site p38 mitogen activated protein kinase inhibitorsUNIV MARYLAND·Filed 2023·Granted Jan 21, 2025·0 cites·18 claims
- 1379US9351963B2Defensin-like molecules as novel antimicrobial agentsUNIV MARYLAND·Filed 2013·Granted May 31, 2016·2 cites·6 claims
- 1478US8796323B2Defensin-like molecules as novel antimicrobial agentsDE LEEUW ERIK·Filed 2011·Granted Aug 5, 2014·3 cites·6 claims
- 1577US8445537B2Compounds that inhibit human DNA ligases and methods of treating cancerTOMKINSON ALAN E·Filed 2009·Granted May 21, 2013·3 cites·16 claims
- 1677US2025353826A1Inhibitors of extracellular signal-regulated kinaseGEN1E LIFESCIENCES INC·Filed 2025·Application pending·0 cites
- 1776US8785499B2Targeting NAD biosynthesis in bacterial pathogensMACKERELL JR ALEXANDER·Filed 2010·Granted Jul 22, 2014·5 cites·6 claims
- 1873US9073896B2Compounds that inhibit human DNA ligases and methods of treating cancerUNIV MARYLAND·Filed 2013·Granted Jul 7, 2015·1 cites·6 claims
- 1971US9943506B2BCL6 inhibitors as anticancer agentsUNIV CORNELL·Filed 2014·Granted Apr 17, 2018·1 cites·7 claims
- 2071US7521463B2Immunomodulatory compoundsUNIV MARYLAND·Filed 2001·Granted Apr 21, 2009·2 cites·23 claims
- 2165US11634381B2RUNX2 transcription factor inhibitors and uses thereofUNIV MARYLAND·Filed 2019·Granted Apr 25, 2023·0 cites·5 claims
- 2265US2024150315A1Beta-2 adrenoreceptor modulators and methods of using sameUNIV MARYLAND·Filed 2023·Application pending·0 cites
- 2363US2007066616A1Inhibitors for extracellular signal-regulated kinase docking domains and uses thereforSHAPIRO PAUL·Filed 2006·Application pending·0 cites
- 2462US2019151324A1NON-CATALYTIC SUBSTRATE-SELECTIVE P38alpha-SPECIFIC MAPK INHIBITORS WITH ENDOTHELIAL-STABILIZING AND ANTI-INFLAMMATORY ACTIVITY, AND METHODS OF USE THEREOFUNIV MARYLAND·Filed 2017·Application pending·0 cites
- 2561US2009299063A1Inhibitors for Extracellular Signal-Regulated Kinase Docking Domains and Uses ThereforSHAPIRO PAUL·Filed 2006·Application pending·0 cites
- 2659US10941114B2Small molecule lipid II inhibitorsUNIV MARYLAND·Filed 2019·Granted Mar 9, 2021·0 cites·15 claims
- 2759US9422302B2Mixed μ agonist/ δ antagonist opioid analgesics with reduced tolerance liabilities and uses thereofUNIV MARYLAND·Filed 2014·Granted Aug 23, 2016·0 cites·13 claims
- 2857US2018373846A1Methods and systems for organic solute sampling of aqueous and heterogeneous environmentsUNIV MARYLAND·Filed 2018·Application pending·0 cites
- 2955US2007099970A1Immunomodulatory compounds that target and inhibit the pY'binding site of tyrosene kinase p56 LCK SH2 domainMACKERELL ALEXANDER·Filed 2006·Application pending·0 cites
- 3053US2023140941A1Non-atp/catalytic site p38 mitogen activated protein kinase inhibitorsUNIV MARYLAND·Filed 2021·Application pending·0 cites
- 3153US2024132484A1Broad spectrum antiviral compounds targeting the ski complexUNIV MARYLAND·Filed 2021·Application pending·0 cites
- 3252US11510908B2Protein translation inhibitors and uses thereofCARRIER FRANCE·Filed 2020·Granted Nov 29, 2022·0 cites·14 claims
- 3352US9757375B2Compounds that inhibit human DNA ligases and methods of treating cancerUNIV MARYLAND·Filed 2015·Granted Sep 12, 2017·0 cites·7 claims
- 3451US2011172234A1Methods and compositions of trail-death receptor agonists/activatorsUNIV TEXAS·Filed 2011·Application pending·0 cites
- 3551US2007196395A1Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domainMACKERELL ALEXANDER·Filed 2003·Application pending·0 cites
- 3651US2012053067A1Method for binding site identification by molecular dynamics simulation (silcs: site identification by ligand competitive saturation)MACKERELL JR ALEXANDER D·Filed 2010·Application pending·0 cites
- 3750US2016267219A1Site-specific fragment identification guided by single-step free energy perturbation calculationsUNIV MARYLAND·Filed 2016·Application pending·0 cites
- 3850US2018300447A1Method for binding site identification by molecular dynamics simulation (silcs: site identification by ligand competitive saturation)UNIV MARYLAND·Filed 2018·Application pending·0 cites
- 3948US2016357945A1Methods and systems for organic solute sampling of aqueous and heterogeneous environmentsUNIV MARYLAND·Filed 2015·Application pending·0 cites
- 4047US10002228B2Method for binding site identification by molecular dynamics simulation (silcs: site identification by ligand competitive saturation)UNIV MARYLAND·Filed 2015·Granted Jun 19, 2018·0 cites·24 claims
- 4147US8476273B2Small molecule inhibitors of Lck SH2 domain bindingHAYASHI JUN·Filed 2008·Granted Jul 2, 2013·0 cites·5 claims
- 4247US2006004085A1Inhibitors of the S100-p53 protein-protein interaction and method of inhibiting cancer employing the sameUNIV MARYLAND·Filed 2005·Application pending·0 cites
- 4346US9701627B2LRRK2 GTP binding inhibitors for treatment of Parkinson's disease and neuroinflammatory disordersUNIV MARYLAND·Filed 2015·Granted Jul 11, 2017·0 cites·6 claims
- 4446US8053477B2Inhibitors of the S100-p53 protein-protein interaction and method of inhibiting cancer employing the sameUNIV MARYLAND·Filed 2003·Granted Nov 8, 2011·0 cites·6 claims
- 4546US2015095007A1Site-specific fragment identification guided by single-step free energy perturbation calculationsUNIV MARYLAND·Filed 2013·Application pending·0 cites
- 4643US2022259180A1Broad spectrum antiviral compounds targeting the ski complexFRIEMAN MATTHEW·Filed 2020·Application pending·0 cites
- 4741US2018110746A1Small molecule inhibitors of tlr2 signalingUNIV MARYLAND·Filed 2016·Application pending·0 cites
- 4840US10961214B2Small molecule lipid II inhibitorsDE LEEUW ERIK·Filed 2016·Granted Mar 30, 2021·0 cites·22 claims
- 4938US2010093867A1Method Of Treating Genetic Disease Caused By Nonsense MutationMATSUDA RYOICHI·Filed 2007·Application pending·0 cites
- 5020US8673913B2SHP-2 phosphatase inhibitorQU CHENG-KUI·Filed 2010·Granted Mar 18, 2014·0 cites·5 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →